Shield Therapeutics plc (LON:STX – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Monday . The stock traded as low as GBX 1.50 ($0.02) and last traded at GBX 1.54 ($0.02), with a volume of 1817725 shares changing hands. The stock had previously closed at GBX 1.50 ($0.02).
Shield Therapeutics Stock Performance
The company has a current ratio of 2.95, a quick ratio of 2.16 and a debt-to-equity ratio of 21.30. The firm’s 50-day simple moving average is GBX 2.88 and its 200-day simple moving average is GBX 5.20. The company has a market capitalization of £11.34 million, a PE ratio of -12.29 and a beta of 0.84.
Shield Therapeutics Company Profile
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Read More
- Five stocks we like better than Shield Therapeutics
- Golden Cross Stocks: Pattern, Examples and Charts
- ASML Fires Warning Shot For Tech Investors
- Why Invest in 5G? How to Invest in 5G Stocks
- Prologis Stock Leading U.S. Logistics Boom
- How to Calculate Options Profits
- Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
